Why Vanda's Stock Is Trading Lower Today - Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA) shares are trading lower on Tuesday, after Citigroup downgraded the stock from Buy to Neutral and announced a price target of $14 per share.

Vanda is a biopharmaceutical company which is engaged in the development and commercialization of therapies to address high unmet medical needs and improves the lives of patients. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant (VLY-686), VTR-297, and VQW-765.

Vanda shares are trading down 6.10% at $10.93 at time of publication on Tuesday. The stock has a 52-week high of $17.85 and a 52-week low of $7.12.

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.

Vanda Pharmaceuticals (NASDAQ:VNDA) shares are trading lower on Tuesday, after Citigroup downgraded the stock from Buy to Neutral and announced a price target of $14 per share.

Vanda shares are trading down 6.10% at $10.93 at time of publication on Tuesday. The stock has a 52-week high of $17.85 and a 52-week low of $7.12.

Gilead Analysts See Questionable Commercial Opportunity For Coronavirus Candidate Remdesivir

VNDAVanda Pharmaceuticals Inc

$8.66-0.23%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.